ImmunityBio, Inc.

As of October 24, 2025, ImmunityBio, Inc. has shifted to a mildly bearish trend, with mixed technical indicators and significant underperformance against the S&P 500, showing a 1-year return of -41.33% compared to the index's 16.90%.

As of October 24, 2025, ImmunityBio, Inc. shows a mildly bearish trend due to mixed technical indicators, with weekly signals suggesting caution and no available return data for comparison against the S&P 500.

As of October 24, 2025, ImmunityBio, Inc. shows a mildly bearish trend, with mixed indicators: weekly MACD is mildly bullish, while monthly MACD is bearish, and the stock has significantly underperformed the S&P 500 with a 1-year return of -41.33%.

As of September 9, 2025, ImmunityBio, Inc. shows a mildly bearish trend with mixed indicators, having outperformed the S&P 500 in the short term but significantly underperformed over the past year.

As of August 12, 2024, ImmunityBio, Inc. is rated as "risky" and overvalued, with negative financial metrics such as a Price to Book Value of -4.70 and a P/E ratio of -5.48, despite a recent short-term gain of 10.04%, contrasting sharply with its long-term 5-year return of -66.43%.

As of August 12, 2024, ImmunityBio, Inc. is rated as "risky" and overvalued due to a negative P/E ratio and poor financial metrics, including a Price to Book Value of -4.70, while its stock has declined 61.98% over the past year compared to a 10.26% increase in the S&P 500.

As of May 30, 2025, ImmunityBio, Inc. has a mildly bearish technical stance, indicated by a mix of mildly bullish weekly MACD momentum and bearish monthly MACD, alongside bearish moving averages and Bollinger Bands on longer time frames.

As of March 2022, the management team of ImmunityBio, Inc. includes Dr. Patrick Soon-Shiong (Executive Chairman), Dr. Barry Simon (President and Chief Administrative Officer), Mr. Frederick Driscoll (Lead Independent Director), and several other directors. This team is responsible for the company's strategic direction and operations.

ImmunityBio, Inc. is a clinical-stage immunotherapy company focused on utilizing the innate immune system to treat cancer and other diseases. As of March 2025, it reported net sales of $17 million and a net loss of $130 million, with a market cap of approximately $2.51 billion.

As of Jun 18, ImmunityBio, Inc. has a market capitalization of $2.51 billion, with net sales of $31.23 million and a net profit of -$409.18 million over the last four quarters. The company's shareholder's funds are -$489.10 million, and total assets are $382.93 million.